You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK):獲得國家藥監局藥品審評中心批准開展TST002(Blosozumab)II期臨牀試驗
格隆匯 07-31 08:07

格隆匯7月31日丨創勝集團-B(06628.HK)發佈公吿,公司已獲得中國國家藥品監督管理局藥品審評中心(CDE)批准,開展TST002 (Blosozumab) II期臨牀試驗。該研究旨在評估 TST002 (Blosozumab)注射液單次及多次靜脈滴注給藥在骨密度降低患者的安全性、耐受性及藥代動力學。

公司執行副總裁、全球藥物開發執行副總裁及首席醫學官Caroline Germa博士表示:“我們很高興收到中國藥監局藥品審評中心的批准。在II期臨牀試驗中,我們將評估降低TST002(Blosozumab)給藥頻率的幾種治療方案,為III期臨牀奠定基礎。我們期待未來能夠充分探索TST002(Blosozumab)的差異性,解決大量骨質疏鬆症患者未被滿足的醫療需求。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account